[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vancomycin-resistant-enterococci-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vancomycin-resistant-enterococci-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609960","phase-2-enteral-vancomycin-as-primary-prophylaxis-against-clostridioides-difficile-infection-in-critically-ill-patients-100609960",false,"NCT07221370","Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients","Inclusion Criteria:\n\n1. Must meet all 3 criteria:\n\n   * Adults aged 18 years and older.\n   * Receiving ≥ 72 hours of a systemic antibiotic during index hospitalization.\n   * Admitted ≥ 72 hours into their index hospitalization.\n2. And must meet 2 additional of the following high-risk criteria\n\n   * Age ≥ 65 years\n   * Previous residence in long-term care facility\n   * Previous proton pump inhibitor use (chronic or as needed)\n   * Inflammatory bowel disease\n   * Immunocompromised state (HIV\u002FAIDS; transplant recipient; receipt of prednisone 20 mg daily for at least one month, immunosuppressants, or chemotherapy)\n   * End stage renal disease (ESRD)\n   * Diabetes mellitus\n   * Receipt of catecholamines (norepinephrine at a rate of ≥ 5 mcg\u002Fmin)\n   * Hospitalized ≤ 30 days prior to the index hospitalization.\n   * Received systemic antibiotics during that prior hospitalization.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Currently incarcerated individuals\n* Individual or legal representative whose informed consent cannot be obtained\n* Subject not expected to survive the ICU stay or subject likely to be considered for palliative or hospice care\n* Receiving concurrent treatment with metronidazole for any indication\n* One-time empiric use of metronidazole is allowed and does not constitute an exclusion criterion\n* Receiving concurrent probiotics\n* Allergic reaction or had a contraindication for use of enteral vancomycin\n* History of prior CDI within the past 90 days of randomization\n* Had suspected active CDI prior to inclusion\n* Infection requiring more than 14 21 days of systemic antibiotics during index hospitalization","ALL","18 Years",{"count":18,"type":19},176,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the drug in this setting. The main questions the trial aims to answer are:\n\n* Does oral vancomycin lower the rate of C.diff infection in high-risk patients?\n* Does C.diff carrier status change the C.diff infection rate as well as clearance of carrier status when vancomycin is used as primary prophylaxis? Researchers will compare the oral, active drug vancomycin to a placebo (a look-alike substance that contains no drug) to determine if vancomycin works to prevent C.diff infection in the hospital.\n\nParticipants will:\n\n* Take oral vancomycin or a placebo while they receive systemic antibiotic(s) for up to five days after the last dose of said systemic antibiotic(s). The treatment of said systemic antibiotic(s) is not to exceed 21 days.\n* When discharged from the hospital, participants will continue to take the study medication in the event he\u002Fshe did not complete the intended course of the study medication while in the hospital.\n* Participants will provide stool sample or rectal swabs for to assess their C.diff carrier status as well as any change in stool microbiome status, including VRE (vancomycin resistant Enterococcus)\n* After completion of the intervention period, participants will be contacted via telephone to assess if they developed diarrhea or any untoward effects of study medication.",[26,27],"Clostridium Difficile Infection","Vancomycin Resistant Enterococci Infection",[29,30,31],"Clostridium difficle infection","primary prophylaxis","Vancomycin resistant enterocci infection","RECRUITING","2025-11-05",{"date":35,"type":36},"2025-11-10","ACTUAL",{"date":38,"type":36},"2024-10-21",{"date":40,"type":19},"2026-12-31",{"name":42,"class":43},"Riverside University Health System Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":53,"type":19},450,[55],"NA","The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[58,59,60,61,62,63,26,64,65,66,67,68,69,70,27,71,72,73,74,75,76,77,78,79,80,81,82],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":85,"type":36},"2024-08-22",{"date":87,"type":36},"2019-07-15",{"date":89,"type":19},"2030-10-31",{"name":91,"class":43},"Chinese University of Hong Kong",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100535955","dynamics-of-colonization-and-infection-by-multidrug-resistant-pathogens-in-immunocompromised-and-critically-ill-patients-100535955","NCT06258551","Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients","DYNAMITE","Inclusion Criteria:\n\n* Admission to an intensive care unit or stem cell transplant unit (for allogeneic stem cell transplantation) within previous 24 hours\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Pregnancy\n* History of inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Gastrointestinal derivation (colostomy, ileostomy, etc.)",true,{"count":101,"type":19},1000,"OBSERVATIONAL","The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. Participants will have the following samples collected during enrollment: stool samples (maximum 2x\u002Fweek), blood draws (1x\u002Fweek), oral swab (1x\u002Fweek).",[105,106,107,70,108,27,109,110],"Antimicrobial Drug Resistance","Antibiotic Resistant Infection","Clostridium Difficile","Extended Spectrum Beta-Lactamase Producing Bacteria Infection","Carbapenem Resistant Bacterial Infection","Vancomycin-Resistant Enterococcal Infection","2024-02-06",{"date":113,"type":36},"2024-02-14",{"date":115,"type":36},"2020-12-08",{"date":117,"type":19},"2026-06",{"name":119,"class":43},"The Methodist Hospital Research Institute",2]